ArticleBJU international2026
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.BJU international · 2026Article
- ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.Annals of surgical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo report long-term oncological outcomes of patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) undergoing bladder-sparing therapy (BST) after bacillus Calmette-Guérin (BCG) failure. PATIENTS AND
methodsWe retrospectively reviewed patients with HR-NMIBC treated from 2000 to 2025 with intravesical therapies after BCG failure, all of whom received salvage gemcitabine/docetaxel (Gem/Doce). Subsequent BST included valrubicin/docetaxel, sequential doxorubicin/gemcitabine alternating with mitomycin-C/docetaxel, and gemcitabine/cabazitaxel with pembrolizumab. Kaplan-Meier analysis estimated recurrence-free survival (RFS), progression-free survival (PFS), cystectomy-free survival (CFS), and cancer-specific survival (CSS).
resultsA total of 85 patients with HR-NMIBC were included of whom 38 (45%) were BCG-unresponsive. The median (interquartile range) follow-up was 86 (43-108) months from induction Gem/Doce. Following Gem/Doce initiation, RFS did not significantly decline with each successive line of salvage therapy: among patients treated with first (Gem/Doce), second, and third line salvage therapy, the 2-year RFS was 47%, 43%, and 39%, respectively (P = 0.68). Overall, the PFS at 5 years was 81% (95% confidence interval [CI] 69-88%). PFS did not significantly decline with each successive salvage line of therapy: among patients treated with first (Gem/Doce), second, and third line salvage therapy, the 2-year PFS was 91%, 88%, and 93%, respectively (P = 0.98). CFS and CSS were 74% (95% CI 62-83%) and 88% (95% CI 79-94%) at 5 years, respectively.
conclusionsMulti-line BST is feasible and can yield durable bladder preservation and oncological control in select patients with HR-NMIBC following BCG failure. Progression-free outcomes remained favourable across successive lines of salvage therapy. These findings support the role of longitudinal BST as an alternative to radical cystectomy in carefully and appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.